胃癌qBiomarker體細(xì)胞突變PCR芯片 Gastric Cancer qBiomarker Mutation PCR Array

科技服務(wù) > PCR芯片實(shí)驗(yàn)服務(wù) > 胃癌qBiomarker體細(xì)胞突變PCR芯片 Gastric Cancer qBiomarker Mutation PCR Array

胃癌qBiomarker體細(xì)胞突變PCR芯片 Gastric Cancer qBiomarker Mutation PCR Array

聯(lián)系購(gòu)買

配送服務(wù)：

運(yùn)費(fèi) ￥0.00

數(shù)量：

（庫(kù)存 9999 件）

產(chǎn)品詳細(xì)

簡(jiǎn)介：	Gastric Cancer qBiomarker Mutation PCR Array 胃癌qBiomarker體細(xì)胞突變PCR芯片
提供商：	SAbiosciences
服務(wù)名稱：	胃癌qBiomarker體細(xì)胞突變PCR芯片
地區(qū)：	美國(guó)

“英拜為您實(shí)驗(yàn)加速”
技術(shù)服務(wù)網(wǎng)址：http://letsgrowganja.com/
服務(wù)熱線：400-696-6643、 18019265738
郵箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

Gastric Cancer qBiomarker Mutation PCR Array

胃癌qBiomarker體細(xì)胞突變PCR芯片

Product	Species	Technology	Cat. No.
Gastric Cancer qBiomarker Mutation PCR Array	Human	Somatic Mutation	SMH-041A

The Human Gastric Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate and comprehensive profiling of the somatic mutations in human gastric cancer samples in the following key genes: APC, BRAF, CDH1, CDKN2A, CTNNB1, ERBB2, FBXW7, HRAS, KRAS, NRAS, PDGFRA, PIK3CA and P53. These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. The utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions has been demonstrated in numerous research studies. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Gastric Cancer qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for studying mutations in the context of cancer and has the potential for discovering and verifying drug target biomarkers for this cancer type and other cancer types in which these mutations were identified. This array includes 81 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human cancer. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent the most frequently recurring somatic mutations compiled from over 2000 gastric cancer samples. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments
胃癌qBiomarker體細(xì)胞突變PCR芯片是一個(gè)翻譯研究工具,用于快速、準(zhǔn)確、全面剖析人胃癌樣本中發(fā)生體細(xì)胞突的癌癥樣本的基因:APC, BRAF, CDH1, CDKN2A, CTNNB1, ERBB2, FBXW7, HRAS, KRAS, NRAS, PDGFRA, PIK3CA and P53.這些突變保證廣泛的研究,以提高致癌作用的理解和鑒定潛在的藥物靶點(diǎn)。已有許多研究通過(guò)單個(gè)和多個(gè)體細(xì)胞突變狀態(tài)信息鑒定關(guān)鍵信號(hào)轉(zhuǎn)導(dǎo)中斷。例如,EGFR和KRAS基因的突變狀態(tài)可以預(yù)測(cè)某些藥物針對(duì)這些分子的生理反應(yīng)。人類胃癌癥qBiomarker體細(xì)胞突變PCR芯片以其全面的內(nèi)容覆蓋范圍，用于研究胃癌的環(huán)境突變且有潛力用于發(fā)現(xiàn)胃癌和這些突變已確定的其他癌癥的靶向藥物的靶標(biāo)。這個(gè)芯片包含81個(gè)DNA突變序列用于檢測(cè)最頻繁的，功能性驗(yàn)證，在人類人類胃癌有生物學(xué)意義的突變。這些突變的選擇根據(jù)全面的體細(xì)胞突變數(shù)據(jù)庫(kù)和同行評(píng)審的科學(xué)文獻(xiàn)，來(lái)自2000多個(gè)胃癌樣本表現(xiàn)最頻繁重復(fù)編譯的體細(xì)胞突變。產(chǎn)品的簡(jiǎn)單格式和操作程序允許在任何常規(guī)的體細(xì)胞突變分析研究實(shí)驗(yàn)室提供實(shí)時(shí)PCR儀器。簡(jiǎn)單的產(chǎn)品模式和操作程序讓任何一個(gè)具備實(shí)時(shí)定量PCR儀的實(shí)驗(yàn)室都可進(jìn)行常規(guī)的體細(xì)胞突變分析。
APC: 4 Assays
The most commonly detected APC inactivation mutations are mainly composed of truncation mutations (due to nonsense mutations and frameshift mutations) and point mutations between codons 1250 and 1578.
BRAF: 2 Assays
There are two major classes of BRAF mutations. One class leads to increased BRAF kinase activity, such as the p. V600E mutation. The other class leads to impaired kinase activity, such as the p.G469A mutation.
CDH1: 1 Assay
The top CDH1 mutations either are missense mutations or frameshift mutations that lead to C-terminal truncation and secreted E-cadherin fragments.
CDKN2A: 1 Assay
The top CDKN2A loss-of-function mutations occur in the consensus ankyrin domain, which leads to inability to form stable complexes with its targets.
CTNNB1: 18 Assays
The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
ERBB2: 2 Assays
The most frequently identified ERBB2 activating mutations cluster in the ERBB2 kinase domain region.
FBXW7: 1 Assay
Typically detected mutations lay in either the third or fourth repeat of the protein's WD40 domain, typically involved in protein-protein interactions.
HRAS: 1 Assay
The most important HRAS mutation in gastric cancer occurs at codon 12.
KRAS: 10 Assays
The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
NRAS: 1 Assay
The most important NRAS mutation in gastric cancer occurs at codon 13.
PDGFRA: 1 Assay
The most frequently identified PDGFRA gain-of-function mutations include deletion, point mutation, and deletion-insertion mutations in regions p.D842-S847 and p.R554-E571 as well as the point mutations p.N659Y and p.T674I.
PIK3CA: 4 Assays
The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
TP53: 35 Assays
The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure.

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS?